$9.61
Today
as of Jul 22, 16:48 ET
Last 30 days
Recent Press Releases & News
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress
Is Eikon Therapeutics, Inc. (EIKN) Stock a Biotech Growth Opportunity Despite Limited Q1 Updates?
Eikon Therapeutics to Join Russell 3000 Index After Annual Reconstitution
Overview
52-week range
$7.90
$17
18% of range
Avg surprise (last 1)
-67.3%
Avg reaction (last 1)
-0.1%
0% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 11, 2026 | Mar/2026 | $-2.46 | $-1.47 | -67.3% | — | -0.1% | earnings |
| Mon Mar 31, 2025 | Mar 2025 | $-26.91 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | OTHER | -$1.61 | — |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Mar 2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Cost of revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | $-87M | — | $-71M |
| Net income | $-83M | — | $-68M |
| EPS (diluted) | $-2.46 | — | $-26.91 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Mar 2025 |
|---|---|---|---|
| Cash & equivalents | $161M | $105M | $205M |
| Inventory | — | — | — |
| Total current assets | $530M | $349M | — |
| Total assets | $851M | $595M | — |
| Long-term debt | — | — | — |
| Total liabilities | $300M | $312M | — |
| Total equity | $551M | $-879M | $-640M |
Implied volatility — last 90 days
No IV snapshots yet for EIKN.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.